I had open-heart surgery (CABG) last Tuesday, got released from the hospital yesterday and wanted everyone to know it went fine - no pain (none at all) and everything is progressing fine in recovery. Best surgeon and staff at Lahey Burlington!

Merry Christmas and Happy New Year to all of my friends! https://t.co/VFB7Hf4JDA

My timeshare at the Ocean Club in Aruba is available for rental 3/11-18/2019. If interested or for more info see my posting on Red Week ( https://t.co/nJcboIZlAo)

Proud to present our role @MassEyeAndEar in the first FDA-approved gene therapy procedure for inherited disease at the pre- #ARVO2018 #FFBCaseyRetinaSummit https://t.co/0QcMoFlmAY @fightblindness @spark_tx

Another scam - we have received 3 calls (from San Fran?), over the last 2 days, claiming an arrest warrant from the IRS. IRS NEVER CALLS! Always notices by mail.

I also wrote about the "London Project" early on: https://t.co/N8sS8vzpGm

The work I reported on was done by Advanced Cell Technology, acquired by @AstellasUS ( https://t.co/OuiDv5xv1l) Amanda-Jane refers to work done @Moorfields in UK.

Thanks for your responses. I still feel that stopping progression of disease in 17/18 patients, and improving vision in 10 is proof that the bolus, when done right - works! Wish that @AstellasUS had continued this research!

In 1977, I flew a "silk purse" made from sows ears under a "lead balloon", until a wind gust dropped all on top of me! https://t.co/vDqN0PgXqW

They have started their Phase IIB trial by expanding to treating an additional 85 patients.

Hank, one of these days, I will try and get the answer to what happened when @AstellasUS took over the ACT/Ocata program. As we both know, they switched from the MA-09 stem cell line to NEDs, but did they have to re-start the trials from the beginning? And, just where are they?

#AAO2017 Does anyone know, or is reporting where the Ocata/@AstellasUS stem cell clinicals stand? Have they resumed Phase III studies yet?

4/4 #AAO2017 Let the dialogue begin. @OphthoMag https://t.co/Ak0NmWa7jW

3/4 #AAO2017 In The Economics of Gene Therapy, I proposed a pricing model for Regen Medicine in Ophthalmology, based on population of patients to be treated, and suggested that an annuity program model, based on performance and duration of efficacy, could be used to pay for it.

2/4 #AAO2017 it is time for the ophthalmic community – the suppliers, practitioners, patients and payers – to start thinking about how much this regenerative medicine treatment is likely to cost, and how patients and the healthcare system will pay for it.

1/4 #AAO2017 What will Ophthalmic Gene Therapy cost and how will we and the healthcare system pay for it? With the likelihood of Spark Therapeutics’ gene therapy treatment for LCA10 to be approved for marketing within the next two to three months,

#AAO2017 Let the dialogue begin. https://t.co/Ak0NmWa7jW

#AAO2017 In The Economics of Gene Therapy, I proposed a pricing model for Regen Medicine in Ophthalmology, based on the population of patients to be treated, and suggested that an annuity program model, based on performance and duration of efficacy, could be used to pay for it.

#AAO2017 it is time for the ophthalmic community – the suppliers, practitioners, patients and payers – to start thinking about how much this regenerative medicine treatment is likely to cost, and how patients and the healthcare system will pay for it.

#AAO2017 What will Ophthalmic Gene Therapy cost and how will we and the healthcare system pay for it? With the likelihood of Spark Therapeutics’ gene therapy treatment for LCA10 to be approved for marketing within the next two to three months,